Literature DB >> 28180031

Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study.

Yu Wang1, Xiang-Yu Zhao1, Lan-Ping Xu1, Xiao-Hui Zhang1, Wei Han1, Huan Chen1, Feng-Rong Wang1, Xiao-Dong Mo1, Yuan-Yuan Zhang1, Xiao-Su Zhao1, Kong Y1, Kai-Yan Liua1, Xiao-Jun Huang2, Xue-Zhong Yu3, Ying-Jun Chang1.   

Abstract

To investigate the effects of non-inherited maternal antigen (NIMA) on clinical outcomes and immune recovery, especially of regulatory T cells (Tregs), in patients who underwent unmanipulated haploidentical transplantation. A retrospective cohort (n = 57) and a prospective cohort (n = 88) were included. All patients received haploidentical allografts from sibling donors. Reconstitution of immune subsets, including Tregs, was determined using multicolor flow cytometry. In the retrospective cohort, the cumulative incidence of grades II-IV acute GVHD in patients with NIMA-mismatched donors was significantly lower than that of cases with NIPA-mismatched donors (14.8% vs. 43.30%, p = 0.018). Patients with higher percentages of CD4+CD25+CD45RA+ T cells (naive Tregs) within CD4+ T cells recovered on day 30 (≥1.55%) experienced a significantly lower incidence of grades II-IV acute GVHD than that of cases with lower percentages of naive Tregs (<1.55%) (13.8% vs. 46.4%, p = 0.010). Multivariate analysis showed that NIMA mismatch and the percentages of naive Tregs were associated with the incidence of grades II-IV acute GVHD [p = 0.050, and 0.031, respectively]. In the prospective cohort, the association of NIMA mismatch [HR = 0.365, 95% CI, 0.169-0.786, p = 0.010] or higher percentages of naive Tregs recovered on day 30 (≥1.55%) [HR = 0.114, 95% CI, 0.027-0.479, p = 0.003] with a lower cumulative incidence of grades II-IV acute GVHD was further demonstrated. No effects of NIMA mismatch on chronic GVHD, transplant-related mortality, relapse, disease-free survival, or overall survival were found. Our results confirmed the role of NIMA mismatch in acute GVHD and provided the first demonstration, based on clinical data, that recovered Tregs may be involved in the effects of NIMA on acute GVHD in a haploidentical transplant setting.

Entities:  

Keywords:  Graft-versus-host disease; haploidentical stem cell transplantation; immune reconstitution; non-inherited maternal antigen; regulatory T cells

Year:  2016        PMID: 28180031      PMCID: PMC5215191          DOI: 10.1080/2162402X.2016.1242546

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  38 in total

1.  Non-T-cell-depleted HLA-haploidentical stem cell transplantation after reduced-intensity conditioning in advanced haematological malignancies based on feto-maternal microchimerism.

Authors:  Chihiro Shimazaki; Shin-ichi Fuchida; Naoya Ochiai; Sonoko Nakano; Noriko Yamada; Ryo Uchida; Masashi Okamoto; Akira Okano; Tohru Inaba; Etsuko Maruya; Hiroh Saji
Journal:  Br J Haematol       Date:  2004-11       Impact factor: 6.998

2.  Long-term survival after HLA-haploidentical SCT from noninherited maternal antigen-mismatched family donors: impact of chronic GVHD.

Authors:  J Kanda; T Ichinohe; C Shimazaki; M Hamaguchi; A Watanabe; H Ishida; T Yoshihara; A Morimoto; N Uoshima; S Adachi; T Inukai; A Sawada; K Oka; M Itoh; M Hino; E Maruya; H Saji; T Uchiyama; Y Kodera
Journal:  Bone Marrow Transplant       Date:  2009-02-16       Impact factor: 5.483

3.  Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism.

Authors:  Chihiro Shimazaki; Naoya Ochiai; Ryo Uchida; Akira Okano; Shin-ichi Fuchida; Eishi Ashihara; Tohru Inaba; Naohisa Fujita; Etsuko Maruya; Masao Nakagawa
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

4.  Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.

Authors:  Yu Wang; Qi-Fa Liu; Lan-Ping Xu; Kai-Yan Liu; Xiao-Hui Zhang; Xiao Ma; Zhi-Ping Fan; De-Pei Wu; Xiao-Jun Huang
Journal:  Blood       Date:  2015-05-04       Impact factor: 22.113

5.  Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.

Authors:  Jon J van Rood; Fausto R Loberiza; Mei-Jie Zhang; Machteld Oudshoorn; Frans Claas; Mitchell S Cairo; Richard E Champlin; Robert Peter Gale; Olle Ringdén; Jill M Hows; Mary H Horowitz
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

6.  Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.

Authors:  Xiao-Jun Huang; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Huan Chen; Wei Han
Journal:  Haematologica       Date:  2007-03       Impact factor: 9.941

7.  Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia.

Authors:  Xiao-Jun Huang; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Yu-Hong Chen; Yu Wang; Wei Han; Huan Chen
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

8.  Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

Authors:  Ana C Alho; Haesook T Kim; Marie J Chammas; Carol G Reynolds; Tiago R Matos; Edouard Forcade; Jennifer Whangbo; Sarah Nikiforow; Corey S Cutler; John Koreth; Vincent T Ho; Philippe Armand; Joseph H Antin; Edwin P Alyea; Joao F Lacerda; Robert J Soiffer; Jerome Ritz
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113

9.  Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.

Authors:  Xiao-Jun Huang; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Huan Chen; Wei Han; Yu-Hong Chen; Xiao-Hui Zhang; Dao-Pei Lu
Journal:  Biol Blood Marrow Transplant       Date:  2009-02       Impact factor: 5.742

Review 10.  How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

Authors:  Ying-Jun Chang; Leo Luznik; Ephraim J Fuchs; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388

View more
  4 in total

1.  Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes.

Authors:  Yu Wang; Ying-Jun Chang; Lu Chen; Lan-Ping Xu; Zhi-Lei Bian; Xiao-Hui Zhang; Chen-Hua Yan; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Oncoimmunology       Date:  2017-09-14       Impact factor: 8.110

2.  Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies.

Authors:  Fei-Fei Tang; Xiang-Yu Zhao; Ming-Rui Huo; Ying-Jun Chang; Wei Han; Yu-Hong Chen; Chen-Hua Yan; Lan-Ping Xu; Xiao-Hui Zhang; Xiao-Jun Huang; Yu Wang
Journal:  Bone Marrow Transplant       Date:  2021-07-08       Impact factor: 5.483

3.  Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia: Effects of CD34+ and CD14+ Cell Doses.

Authors:  Le-Qing Cao; Lan-Ping Xu; Xiao-Hui Zhang; Yu Wang; Yan-Rong Liu; Kai-Yan Liu; Xiao-Jun Huang; Ying-Jun Chang
Journal:  Chin Med J (Engl)       Date:  2018-09-20       Impact factor: 2.628

Review 4.  Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.

Authors:  Susanne H C Baumeister; Benedetta Rambaldi; Roman M Shapiro; Rizwan Romee
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.